Drugs / AT13148
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01585701 | May 2012 → Jan 2018 | cancer | Cancer Research UK | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2013-01-16 | Astex Pharmaceuticals, Inc. | Regulatory Cancer Research UK and Cancer Research Technology Initiate AT13148 Clinical Trial to Treat Several Cancer Types astx.com ↗
Cancer Research UK and its commercial arm Cancer Research Technology (CRT) are launching a trial of an experimental drug shown to simultaneously block many enzymes that control cancer cell growth and death. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2013-01-16 | Astex Pharmaceuticals, Inc. | Cancer Research UK and Cancer Research Technology Initiate AT13148 Clinical Trial to Treat Several Cancer Types astx.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AT13148 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01585701 ↗ |
| Action | Inhibit | “It blocks several different chemical messengers (enzymes) called AGC kinase proteins.” NCT01585701 ↗1“MAP kinase-activated protein kinase 2 inhibitor” CHEMBL3544960 ↗ |
| Modality | Small molecule | — CHEMBL3544960 ↗ |
| Route | Oral | “AT13148 Given Orally” NCT01585701 ↗ |
| Target | MAPKAPK2 | “MAP kinase-activated protein kinase 2 inhibitor” CHEMBL3544960 ↗ |